Elie El Rassy1, Tarek Assi1,2, Ziad Bakouny1, Fadi El Karak1, Nicholas Pavlidis3, Marwan Ghosn1. 1. Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. 2. Department of Medical Oncology, Institut Gustave Roussy, Université Paris-Saclay, Villejuif F-94805, France. 3. University of Ioannina, Ioannina, Greece.
Abstract
AIM: The literature lacks direct evidence comparing the different regimens evaluated in the second-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). METHODS: We conducted a network meta-analysis (NMA) of the randomized controlled Phase III trials reporting on the second-line drug treatment options in R/M SCCHN. RESULTS: The eligible trials included 11 regimens among which six targeted therapies, two immune checkpoint inhibitors and three chemotherapy regimens. Only nivolumab has shown statistically significant superiority over methotrexate in terms of overall survival (HR: 0.64; 95% CI: 0.43-0.96) and objective response rate (OR: 2.51; 95% CI: 1.07-5.86). CONCLUSION: Based on the efficacy and safety outcomes of this network meta-analysis, nivolumab seems the most favorable regimen inthe management of R/M SCCHN.
AIM: The literature lacks direct evidence comparing the different regimens evaluated in the second-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). METHODS: We conducted a network meta-analysis (NMA) of the randomized controlled Phase III trials reporting on the second-line drug treatment options in R/M SCCHN. RESULTS: The eligible trials included 11 regimens among which six targeted therapies, two immune checkpoint inhibitors and three chemotherapy regimens. Only nivolumab has shown statistically significant superiority over methotrexate in terms of overall survival (HR: 0.64; 95% CI: 0.43-0.96) and objective response rate (OR: 2.51; 95% CI: 1.07-5.86). CONCLUSION: Based on the efficacy and safety outcomes of this network meta-analysis, nivolumab seems the most favorable regimen inthe management of R/M SCCHN.
Entities:
Keywords:
metastatic; platinum refractory; recurrent; second line; squamous cell carcinoma of the head and neck
Authors: Ananya Pareek; Apurva A Patel; Mukesh Kumar; Philip G Kuttikat; Harshavardhan Annadanam; Shantanu Pendse; Naseer Mohammed; Harsha P Panchal Journal: South Asian J Cancer Date: 2021-12-31
Authors: Lisa Morkramer; Maren Geitner; Daniel Boeger; Jens Buentzel; Holger Kaftan; Andreas H Mueller; Thomas Ernst; Orlando Guntinas-Lichius Journal: J Cancer Res Clin Oncol Date: 2021-01-31 Impact factor: 4.553